Healthcare & Life Sciences / Monitoring, Imaging & Diagnostics Tech
Best Liquid Biopsy Cancer Screening Companies
What is Liquid Biopsy Cancer Screening?
The liquid biopsy cancer screening market offers a non-invasive alternative to traditional tissue biopsies for detecting cancer. This market includes various solutions such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) tests, which can detect cancer at an early stage and monitor treatment effectiveness. The liquid biopsy method is less invasive, faster, and more cost-effective than traditional biopsies. Additionally, liquid biopsy tests can be used for a range of cancers, including lung, breast, colorectal, and prostate cancer. As the demand for personalized medicine and targeted therapies increases, the liquid biopsy cancer screening market is expected to grow significantly in the coming years.
Expert Collections
Market Map
Similar Markets
Do you compete within Liquid Biopsy Cancer Screening?
Reach more buyers.
Your future customers are researching their next tech solution on CB Insights. Make sure they can find you.
Top Liquid Biopsy Cancer Screening Companies

QIAGEN is a leading provider of Sample to Insight solutions in the molecular diagnostics and life sciences research sectors. The company offers technologies for isolating and processing DNA, RNA, and proteins, as well as assay development, bioinformatics software, and automation solutions to facilitate seamless and cost-effective workflows. QIAGEN primarily serves the healthcare and life sciences industries, including academia, pharmaceutical R&D, and industrial applications such as forensics. It was founded in 1984 and is based in Hilden, Germany.
Known Partners
AstraZeneca, University of Montana, International Panel Physicians Association, and 1 more
Known Customers
Danish National Genome Center, Denovo Biopharma, U.S. Department of Defense, and 2 more

Veracyte is a global diagnostics company focused on providing high-value insights for cancer diagnosis and treatment. The company offers a suite of molecular tests and genomic classifiers designed to assist clinicians in making informed decisions, thereby helping patients avoid unnecessary procedures and receive timely treatment. Veracyte's products are utilized across various sectors of the healthcare industry, including oncology and personalized medicine. It was founded in 2008 and is based in South San Francisco, California.
Known Partners
Subscribe, Subscribe, Subscribe, and 2 more
Known Customers
Subscribe

Exact Sciences focuses on the eradication of cancer through the development of diagnostic tests. It operates within the healthcare and biotechnology. It offers a range of tests aimed at preventing cancer, detecting it at an early stage, and guiding its successful treatment. These tests are primarily used in the healthcare industry for cancer diagnosis and treatment. It was founded in 1995 and is based in Madison, Wisconsin.
Known Partners
Subscribe, Subscribe, Subscribe, and 2 more
Known Customers
Subscribe, Subscribe, Subscribe
All Companies in Liquid Biopsy Cancer Screening

Caris focuses on molecular science, specifically in the domain of cancer care. The company offers services such as molecular profiling, blood profiling, and tissue profiling, which provide comprehensive molecular information to help oncologists create personalized treatment plans for cancer patients. It primarily sells to the healthcare industry, particularly oncology. It was founded in 1996 and is based in Irving, Texas.

Delfi Diagnostics is a company focused on early cancer detection, operating in the healthcare and biotechnology sectors. The company's main service involves the use of novel machine-learning algorithms to analyze fragments of cell-free deoxyribonucleic acid (DNA), which allows for the accurate detection of cancer from a single blood sample. It primarily serves the healthcare industry. It was founded in 2019 and is based in Palo Alto, California.
Known Partners
Subscribe, Subscribe
Known Customers
Subscribe
Key People
Subscribe, Subscribe, Subscribe, and 2 more

Epic Sciences is a company focused on advancing the treatment and management of cancer through novel diagnostics within the healthcare sector. The company offers a comprehensive cancer profiling platform that utilizes a liquid biopsy to detect genetic and molecular changes in cancer, providing insights for clinicians and drug development professionals. Epic Sciences' main services include the detection and characterization of rare cells such as circulating tumor cells (CTCs), ctDNA gene panel testing, and immune-cell analysis, which aid in personalizing treatment and monitoring drug resistance. It was founded in 2008 and is based in San Diego, California.
Known Partners
Subscribe, Subscribe, Subscribe, and 2 more
Key People
Subscribe, Subscribe, Subscribe, and 2 more

Freenome serves as a biotechnology company that focuses on early cancer detection through advanced diagnostic tools. The company develops blood tests that identify early signs of cancer by analyzing biomarkers from tumor and non-tumor sources using a multiomics platform. Its tests are designed to be non-invasive and accessible, aiming to detect various types of cancer at its most treatable stages. It was founded in 2014 and is based in South San Francisco, California.
Known Partners
Subscribe, Subscribe, Subscribe, and 1 more
Known Customers
Subscribe
Key People
Subscribe, Subscribe, Subscribe, and 2 more

GRAIL is a healthcare company focused on the early detection of cancer and precision oncology. The company main offerings include the Galleri test, a multi-cancer early detection test that screens for various cancers using blood samples by analyzing DNA methylation patterns with machine learning algorithms. GRAIL was formerly known as PSC15. It was founded in 2016 and is based in Menlo Park, California.

Guardant Health is a precision medicine company with a focus on oncology, providing advanced blood and tissue tests to inform treatment decisions for cancer patients. The company offers FDA-approved blood tests for colorectal cancer screening and a suite of products designed to support personalized treatment plans based on biomarker analysis and circulating tumor DNA. Guardant Health's solutions are utilized by healthcare providers, biopharma companies, and researchers seeking to improve clinical outcomes through data-driven insights. It was founded in 2012 and is based in Redwood City, California.
Known Partners
Subscribe, Subscribe, Subscribe, and 2 more
Known Customers
Subscribe

Harbinger Health is focused on fundamentally transforming cancer care through early detection and prevention within the healthcare sector. The company offers blood-based tests that enable the detection of cancer in its earliest stages, utilizing artificial intelligence and insights into cancer biology to identify pre-disease states. Harbinger Health's solutions aim to make cancer screening accessible and affordable, contributing to a proactive approach in cancer care. It was founded in 2018 and is based in Cambridge, Massachusetts.
Known Partners
Subscribe
Key People
Subscribe, Subscribe, Subscribe, and 2 more

Natera operates as a clinical genetic testing company. It offers a range of tests to identify diseases such as breast cancer, bladder cancer, lung cancer, gynecologic cancer, and more. The company was formerly known as Gene Security Network. The company was founded in 2004 and is based in Austin, Texas.
Known Partners
Subscribe, Subscribe, Subscribe, and 2 more
Known Customers
Subscribe

NeoGenomics Laboratories is a company focused on cancer diagnostics within the healthcare sector. The company offers a range of diagnostic services including cancer cytogenetics, hematologic and solid tumor FISH testing, flow cytometry, and molecular oncology tests. These services are primarily aimed at the healthcare industry, including hospital and private pathology laboratories, office-based oncologists, and academic institutions. It was founded in 2001 and is based in Fort Myers, Florida.
Known Partners
Subscribe, Subscribe, Subscribe
Known Customers
Subscribe

Personal Genome Diagnostics (PGDx) develops tests for cancer at the genomic level, which incorporate sequencing algorithms to find alterations in genomes associated with cancer. The company is developing tests of both tissue samples and blood, the latter of which is known as "liquid biopsy." It is based in Baltimore, Maryland. On December 23rd, 2021, Personal Genome Diagnostics was acquired by LabCorp at a valuation between $450M and $575M.
Known Partners
Subscribe, Subscribe, Subscribe
Known Customers
Subscribe, Subscribe, Subscribe
Key People
Subscribe, Subscribe, Subscribe, and 2 more

Singlera Genomics specializes in the development of liquid biopsy technologies for early cancer detection within the biotechnology sector. The company offers analysis reagents and software designed to determine methylation haplotypes in cell-free DNA, with assays capable of detecting cancer significantly earlier than traditional methods. Singlera's products provide cancer diagnostics through non-invasive testing and advanced bioinformatics. It was founded in 2014 and is based in Yangzhou, China.
Known Partners
Subscribe, Subscribe
Key People
Subscribe, Subscribe, Subscribe, and 1 more

Universal DX specializes in the development of blood-based diagnostic tests for early cancer detection within the healthcare sector. Its offerings include liquid biopsy tests that utilize a combination of multi-omics, computational biology, and machine learning to detect cancers, such as colorectal cancer, through a blood test. Universal DX's products are designed to identify cancer at its earliest stages, aiming to make the disease preventable and curable. The company was founded in 2012 and is based in Seville, Spain.
Key People
Subscribe, Subscribe
Our Methodology
The ESP matrix leverages data and analyst insight to identify and rank leading private-market companies in a given technology landscape.
What is Liquid Biopsy Cancer Screening?
The liquid biopsy cancer screening market offers a non-invasive alternative to traditional tissue biopsies for detecting cancer. This market includes various solutions such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) tests, which can detect cancer at an early stage and monitor treatment effectiveness. The liquid biopsy method is less invasive, faster, and more cost-effective than traditional biopsies. Additionally, liquid biopsy tests can be used for a range of cancers, including lung, breast, colorectal, and prostate cancer. As the demand for personalized medicine and targeted therapies increases, the liquid biopsy cancer screening market is expected to grow significantly in the coming years.
Expert Collections
Market Map
Similar Markets
Do you compete within Liquid Biopsy Cancer Screening?
Reach more buyers.
Your future customers are researching their next tech solution on CB Insights. Make sure they can find you.